AHA includes paired VNS in 2026 stroke rehabilitation guideline
Mobia Medical announced that the 2026 guideline from the American Heart Association and American Stroke Association, published in Stroke, recognizes implantable paired vagus nerve stimulation paired with high-dose task-specific training as a treatment option to improve upper-limb function in chronic stroke survivors. The company says its Vivistim Paired VNS System is the only FDA-approved device delivering this approach, and the guideline also highlights continuity of care, high-dose task-specific therapy, and patient-specific outcome evaluation. The recognition may influence clinical practice and further evidence generation, though the guideline does not endorse any specific manufacturer.
AHA guideline recognizes paired VNS as a treatment option.
Context
The American Heart Association and American Stroke Association published the 2026 guideline. The guideline lists paired VNS as a treatment option for chronic stroke upper-limb impairment. Clinical use and evidence collection could increase…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked